• Strategic leadership and management • Accountable and responsible for building, developing and retaining the global team of gCSM • Oversee the delivery and goal achievement of projects within the designated program(s) • Collaborate with the other GCPLs to define and implement strategies and key priorities across-programs • Provide clinical operational insight to drive the program strategy and ensure excellence in execution • Create and be accountable for the annual program budget and resource forecasts • Conduct regular program review meetings to mentor, support, and ensure all studies are tracking to the DCT/DRC-approved budget and timeline • Identify and drive process improvement initiatives

• Lead global HEOR/RWE strategy and evidence generation activities for the BTK degrader asset across product lifecycle, ensuring alignment with cross-functional objectives • Develop and execute integrated value evidence generation plan, including disease burden, treatment patterns, comparative effectiveness, indirect comparisons, economic modeling, and patient-centered outcomes to demonstrate clinical and economic value • Design and execute real-world evidence and comparative effectiveness studies using various real-world data sources including claims and electronic health records to support differentiation • Collaborate with cross-functional partners on JCA/HTA submissions and lead key HEOR deliverables timely including indirect comparisons and economic modeling • Lead development of Global Value Dossiers and US AMCP dossier to support reimbursement submissions and value communication • Drive scientific dissemination of HEOR/RWE evidence through abstracts, manuscripts, and congress presentations and omnichannel distributions

• Oversee major transformation projects • Ensure alignment with organizational objectives and delivering measurable outcomes • Collaborate with business owners and stakeholders to define program strategy and roadmap and manage execution • Build strong relationships with senior leaders and internal and external stakeholders • Establish metrics and KPIs to track the progress and success of transformation projects • Identify and mitigate risks associated with transformation projects • Drive overall cross-functional project management of transformation initiatives • Act as a key voice for change

• The Regional Medical Scientific Director (RMSD) is a credentialed (i.e., PhD, PharmD, OD, DO, or MD) therapeutic and disease expert who engages in bidirectional exchange of scientific or medical information with Scientific Leaders (SLs). • The role provides balanced, factual, scientific information about non-product areas of interest to the Company and replies to scientific questions from SLs, including questions about Company products. • The work of an RMSD is aligned to: Scientific Exchange, Research, Scientific Congress Support, and Scientific Insights. • RMSDs liaise between the scientific community and the Company to enhance the comprehension of scientific foundations and goals for approved, in-development, and active Company-sponsored trials and/or investigator-sponsored research studies. • The RMSD serves as a role model for other field medical team members in ways that include on-boarding and/or sharing of therapeutic expertise. • Develops professional relationships and engages with national and regional SLs to ensure access to company-approved medical and scientific information on areas of therapeutic interest and Company products. • Conducts peer-to-peer scientific discussions and maintains a reliable presence with those SLs to ensure they have a medical contact within the company. • Addresses scientific questions and directs SL inquiries on issues outside of RMSD scope (e.g., grants) to appropriate company resources consistent with applicable policies. • Maintains current knowledge and comprehension of dynamic scientific and clinical environment in the Company's Areas of Interest (AOI) for the RMSD’s specific therapeutic area. • Upon request from Global Center for Scientific Affairs (GCSA), initiates discussions with SLs and/or potential investigators that include scientific/data exchange within our AOI to determine the alignment with our research strategies, studies concepts, scientific merit, and qualifications for a specific compound or trial. • Enhances the comprehension of the scientific foundations and goals of investigator-sponsored research. • Identifies barriers to patient enrollment and retention efforts to achieve study milestones. • Recommends study sites and identifies potential investigators to participate in phase II-IV clinical development programs, conducts Site Initiation Visits (SIVs), and detects barriers to patient enrollment and retention efforts to achieve study milestones. • Addresses questions from investigators and provides information regarding participation in Company-sponsored clinical studies.